Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2026The Journal of Clinical Endocrinology & Metabolism

Quadruple therapy with RASi, SGLT2i, nsMRA, and GLP-1RA provides cardiorenal protection in CKD and T2D.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Combined use of GDMT for CKD with T2D remains uncommon, partly due to the absence of specific guidance on implementing combination treatment.

Does combination GDMT (RASi, SGLT2i, nsMRA, GLP-1RA) improve cardiorenal risk reduction in patients with CKD and T2D?

Design

Review and practical guidance

Key result

Quadruple combination therapy with RASi, SGLT2i, nsMRA, and GLP-1RA provides independent cardiorenal protection in patients with chronic kidney disease and type 2 diabetes.

Authors

MMMai MohsenTYTae Won YiLFLabib Imran Faruque

Discussion

Loading...

Member takes

Overview

Practical algorithm should overcome inertia with quadruple GDMT in CKD-T2D; extends evidence from individual agents to full combination strategy.

Key Points

  • To evaluate combination treatment options for managing chronic kidney disease in patients with type 2 diabetes and propose practical guidance for implementation.
  • Conducted a literature review using PubMed
  • Focused on clinical guidelines and randomized controlled trials
  • Developed a practical algorithm for combination treatment
  • Combination therapies are supported by multiple clinical guidelines
  • Early cardiovascular and kidney protection observed with combined agents
  • Uncertainty remains on optimal medication initiation order and side effect management

Structured PICO

Does combination GDMT (RASi, SGLT2i, nsMRA, GLP-1RA) improve cardiorenal risk reduction in patients with CKD and T2D?

P
Population
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D)
I
Intervention
Combination guideline-directed medical treatments (GDMT) including renin-angiotensin system inhibitors (RASi), sodium glucose cotransporter-2 inhibitors (SGLT2i), nonsteroidal mineralocorticoid receptor antagonists (nsMRA), and glucagon-like peptide-1 receptor agonists (GLP-1RA)

A proposed practical algorithm for implementing quadruple combination therapy (RASi, SGLT2i, nsMRA, GLP-1RA) aims to overcome clinical inertia and improve cardiorenal outcomes in patients with CKD and T2D.

Cite This Study

Mohsen et al. (2026) studied this question. Quadruple combination therapy with RASi, SGLT2i, nsMRA, and GLP-1RA provides independent cardiorenal protection in patients with chronic kidney disease and type 2 diabetes.

synapsesocial.com/papers/69df2ba0e4eeef8a2a6b0a74https://doi.org/10.1210/clinem/dgag163
View Full Paper
Ask AI
Bookmark
Share